263 related articles for article (PubMed ID: 26783066)
41. Neurokinin-1 activation affects EGFR related signal transduction in triple negative breast cancer.
Wang JG; Yu J; Hu JL; Yang WL; Ren H; Ding D; Zhang L; Liu XP
Cell Signal; 2015 Jul; 27(7):1315-24. PubMed ID: 25817575
[TBL] [Abstract][Full Text] [Related]
42. Puerariae radix isoflavones and their metabolites inhibit growth and induce apoptosis in breast cancer cells.
Lin YJ; Hou YC; Lin CH; Hsu YA; Sheu JJ; Lai CH; Chen BH; Lee Chao PD; Wan L; Tsai FJ
Biochem Biophys Res Commun; 2009 Jan; 378(4):683-8. PubMed ID: 19013426
[TBL] [Abstract][Full Text] [Related]
43. Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine.
Nhukeaw T; Temboot P; Hansongnern K; Ratanaphan A
BMC Cancer; 2014 Feb; 14():73. PubMed ID: 24507701
[TBL] [Abstract][Full Text] [Related]
44. Effects of soy isoflavones on apoptosis induction and G2-M arrest in human hepatoma cells involvement of caspase-3 activation, Bcl-2 and Bcl-XL downregulation, and Cdc2 kinase activity.
Su SJ; Chow NH; Kung ML; Hung TC; Chang KL
Nutr Cancer; 2003; 45(1):113-23. PubMed ID: 12791511
[TBL] [Abstract][Full Text] [Related]
45. Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells.
Tanei T; Choi DS; Rodriguez AA; Liang DH; Dobrolecki L; Ghosh M; Landis MD; Chang JC
Breast Cancer Res; 2016 Jan; 18(1):6. PubMed ID: 26757880
[TBL] [Abstract][Full Text] [Related]
46. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
47. Anticancer Effect of Benzimidazole Derivatives, Especially Mebendazole, on Triple-Negative Breast Cancer (TNBC) and Radiotherapy-Resistant TNBC In Vivo and In Vitro.
Choi HS; Ko YS; Jin H; Kang KM; Ha IB; Jeong H; Song HN; Kim HJ; Jeong BK
Molecules; 2021 Aug; 26(17):. PubMed ID: 34500557
[TBL] [Abstract][Full Text] [Related]
48. Genomic and GeneChip expression profiling reveals the inhibitory effects of Amorphophalli Rhizoma in TNBC cells.
Wu C; Chen M; Zhang Q; Yu L; Zhu J; Gao X
J Ethnopharmacol; 2019 May; 235():206-218. PubMed ID: 30731183
[TBL] [Abstract][Full Text] [Related]
49. Comprehensive proteomics and sialiomics of the anti-proliferative activity of safranal on triple negative MDA-MB-231 breast cancer cell lines.
Zarrineh M; Ashrafian S; Jensen P; Nawrocki A; Ansari AM; Rezadoost H; Ghassempour A; Larsen MR
J Proteomics; 2022 May; 259():104539. PubMed ID: 35240313
[TBL] [Abstract][Full Text] [Related]
50. Oestrogen causes G2/M arrest and apoptosis in breast cancer cells MDA-MB-231.
Nomoto S; Arao Y; Horiguchi H; Ikeda K; Kayama F
Oncol Rep; 2002; 9(4):773-6. PubMed ID: 12066207
[TBL] [Abstract][Full Text] [Related]
51. Mapping Novel Metabolic Nodes Targeted by Anti-Cancer Drugs that Impair Triple-Negative Breast Cancer Pathogenicity.
Roberts LS; Yan P; Bateman LA; Nomura DK
ACS Chem Biol; 2017 Apr; 12(4):1133-1140. PubMed ID: 28248089
[TBL] [Abstract][Full Text] [Related]
52. Genistein induces growth inhibition and G2/M arrest in nasopharyngeal carcinoma cells.
Han H; Zhong C; Zhang X; Liu R; Pan M; Tan L; Li Y; Wu J; Zhu Y; Huang W
Nutr Cancer; 2010; 62(5):641-7. PubMed ID: 20574925
[TBL] [Abstract][Full Text] [Related]
53. Anticancer effects of methotrexate in combination with α‑tocopherol and α‑tocopherol succinate on triple‑negative breast cancer.
Wei CW; Yu YL; Chen YH; Hung YT; Yiang GT
Oncol Rep; 2019 Mar; 41(3):2060-2066. PubMed ID: 30628707
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
[TBL] [Abstract][Full Text] [Related]
55. Molecular mechanism of anti-cancer activity of phycocyanin in triple-negative breast cancer cells.
Ravi M; Tentu S; Baskar G; Rohan Prasad S; Raghavan S; Jayaprakash P; Jeyakanthan J; Rayala SK; Venkatraman G
BMC Cancer; 2015 Oct; 15():768. PubMed ID: 26499490
[TBL] [Abstract][Full Text] [Related]
56. Development of CAPER peptides for the treatment of triple negative breast cancer.
Chilewski SD; Bhosale D; Dees S; Hutchinson I; Trimble R; Pontiggia L; Mercier I; Jasmin JF
Cell Cycle; 2020 Feb; 19(4):432-447. PubMed ID: 31931653
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic Effects of Dietary Soybean Genistein on Triple-Negative Breast Cancer via Regulation of Epigenetic Mechanisms.
Sharma M; Arora I; Chen M; Wu H; Crowley MR; Tollefsbol TO; Li Y
Nutrients; 2021 Nov; 13(11):. PubMed ID: 34836197
[TBL] [Abstract][Full Text] [Related]
58. Trichostatin A inhibits proliferation of triple negative breast cancer cells by inducing cell cycle arrest and apoptosis.
Song X; Wu JQ; Yu XF; Yang XS; Yang Y
Neoplasma; 2018 Nov; 65(6):898-906. PubMed ID: 30334455
[TBL] [Abstract][Full Text] [Related]
59. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
[TBL] [Abstract][Full Text] [Related]
60. Maximiscin Induces DNA Damage, Activates DNA Damage Response Pathways, and Has Selective Cytotoxic Activity against a Subtype of Triple-Negative Breast Cancer.
Robles AJ; Du L; Cichewicz RH; Mooberry SL
J Nat Prod; 2016 Jul; 79(7):1822-7. PubMed ID: 27310425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
